FHND1002 for ALS Treatment: Phase 2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2028-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase II clinical trial evaluating the effectiveness and safety of an investigational drug, FHND1002 granules, in adults with Amyotrophic Lateral Sclerosis (ALS).

The main goals are:

To determine if FHND1002 can slow the progression of ALS compared to a placebo.

To assess the safety and tolerability of two different doses of FHND1002 (100mg and 200mg) in ALS patients.

Approximately 180 participants will be randomly assigned (like flipping a coin) to one of three groups:

FHND1002 100mg once daily

FHND1002 200mg once daily

Placebo (an inactive substance) once daily Assignment will consider disease severity (ALSFRS-R score) and where symptoms started (Limb vs. Bulbar). Participants can continue taking stable doses of approved ALS medications (like riluzole or edaravone) or be on no medication.

The study consists of:

A Screening Period (up to 4 weeks).

A Double-Blind Treatment Period (48 weeks).

During the 48-week treatment period:

Participants will take their assigned granules orally once daily (with or without food).

They will attend clinic visits at Weeks 2, 4, 12, 24, 36, and 48 for safety checks.

Effectiveness will be measured at Weeks 12, 24, 36, and 48 using standard ALS assessments, including the ALS Functional Rating Scale-Revised (ALSFRS-R), breathing tests (FVC%), and quality of life/questionnaires (ROADS, ALSAQ-5).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults

NCT06782958

Amyotrophic Lateral Sclerosis (ALS)

ENROLLING_BY_INVITATION PHASE1

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

NCT05923905

Sporadic and Familial Amyotrophic Lateral Sclerosis

RECRUITING PHASE4

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631

Amyotrophic Lateral Sclerosis

COMPLETED PHASE2

A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01935518

Amyotrophic Lateral Sclerosis

UNKNOWN PHASE2

A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)

NCT00230074

Amyotrophic Lateral Sclerosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis (ALS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants are randomized in a 1:1:1 ratio to three parallel arms:

* Arm 1: FHND1002 100mg granules + standard ALS care
* Arm 2: FHND1002 200mg granules + standard ALS care
* Arm 3: Matching placebo granules + standard ALS care Stratification factors: 1) Baseline ALSFRS-R (≥40 vs \<40); 2) Site of onset (limb vs bulbar).

Double-blind treatment period: 48 weeks.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FHND1002 100mg

Participants receive FHND1002 granules 100mg orally once daily for 48 weeks. Administration may occur fasting or with food. Concurrent stable ALS medications (e.g., edaravone/riluzole) are permitted if maintained ≥4 weeks prior to enrollment and unchanged during the study. Standard ALS care continues throughout.

Group Type EXPERIMENTAL

FHND1002 100mg

Intervention Type DRUG

Investigational oral granules containing 100mg FHND1002 (chemical entity: 3-n-butylphthalide derivative). Administered once daily for 48 weeks. Granules are packaged in unit-dose sachets with identical appearance across all study arms. Participants dissolve contents in water prior to ingestion. Stability testing confirms compatibility with fasting or fed conditions.

FHND1002 200mg

Participants receive FHND1002 granules 200mg orally once daily for 48 weeks. Administration may occur fasting or with food. Pre-existing stable ALS therapies (edaravone/riluzole) are allowed if dose-stable for ≥4 weeks pre-randomization and maintained during the trial. Standard supportive care is provided.

Group Type EXPERIMENTAL

FHND1002 200mg

Intervention Type DRUG

Investigational oral granules containing 200mg FHND1002 (3-n-butylphthalide derivative). Delivered as two 100mg sachets or one 200mg sachet to maintain blinding. Daily dosing regimen for 48 weeks. Granule composition matches 100mg formulation in excipients and organoleptic properties.

Placebo

Participants receive matching placebo granules orally once daily for 48 weeks. Administration conditions (fasting/with food) mirror active arms. Background ALS medications (edaravone/riluzole) are permitted if stabilized ≥4 weeks before enrollment and unchanged throughout the study. Standard ALS management continues.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo granules identical to active intervention in appearance, taste, packaging, and administration method. Contains inert excipients (microcrystalline cellulose, lactose monohydrate) without active

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FHND1002 100mg

Investigational oral granules containing 100mg FHND1002 (chemical entity: 3-n-butylphthalide derivative). Administered once daily for 48 weeks. Granules are packaged in unit-dose sachets with identical appearance across all study arms. Participants dissolve contents in water prior to ingestion. Stability testing confirms compatibility with fasting or fed conditions.

Intervention Type DRUG

FHND1002 200mg

Investigational oral granules containing 200mg FHND1002 (3-n-butylphthalide derivative). Delivered as two 100mg sachets or one 200mg sachet to maintain blinding. Daily dosing regimen for 48 weeks. Granule composition matches 100mg formulation in excipients and organoleptic properties.

Intervention Type DRUG

Placebo

Placebo granules identical to active intervention in appearance, taste, packaging, and administration method. Contains inert excipients (microcrystalline cellulose, lactose monohydrate) without active

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must be ≥18 years of age at the time of signing the informed consent form.
* Subjects must have a diagnosis of Amyotrophic Lateral Sclerosis (ALS) meeting the revised El Escorial World Federation of Neurology criteria categories including Clinically Definite ALS, Clinically Probable ALS, Laboratory-supported Probable ALS, or Clinically Possible ALS.
* Subjects must demonstrate a documented mean monthly decline of ≥0.5 points in the ALS Functional Rating Scale-Revised (ALSFRS-R) score since initial diagnosis.
* During screening, subjects must exhibit a percent predicted forced vital capacity (FVC%) ≥70%; note that use of non-invasive ventilation (NIV) is exclusionary.
* Disease duration must be ≤2 years calculated from the onset of the first ALS-related symptom.
* At screening, subjects must have an ALSFRS-R total score ≥30 with a swallowing function subscore ≥2 and all respiratory-related subscores at 4 points.
* Subjects must have a Body Mass Index (BMI) ≥18.5 kg/m².
* Subjects may or may not be receiving stable therapeutic doses of approved ALS medications (e.g., edaravone, riluzole) prior to enrollment, provided any existing regimen remains unchanged throughout the study.
* Subjects must demonstrate ability to understand study procedures, willingness to comply, voluntary participation, and provide signed informed consent.

Exclusion Criteria

* Subjects with coexisting neurological disorders that may mimic ALS symptoms or interfere with efficacy assessment (e.g., cervical/lumbar spondylosis, dementia, history of seizures except childhood febrile seizures) will be excluded.
* Subjects exhibiting motor conduction block or sensory nerve conduction abnormalities on electromyography (EMG) testing will be excluded.
* Subjects with any history of spinal surgery within 3 months prior to screening will be excluded.
* Subjects showing clinically significant laboratory abnormalities at screening including aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>1.5 × upper limit of normal (ULN), or serum creatinine (Scr) \> ULN will be excluded.
* Subjects with severe/uncontrolled cardiac, hepatic, renal, hematologic, or neoplastic diseases, or active severe psychiatric disorders will be excluded.
* Exclusion applies to pregnant or lactating women, and subjects planning pregnancy during the study or within 3 months post-treatment; participants of childbearing potential unwilling to use highly effective contraception throughout the study and for 3 months after last dose are excluded.
* Subjects with known or suspected hypersensitivity to FHND1002 or its excipients will be excluded.
* Subjects who have participated in another investigational drug/device trial within 1 month prior to screening will be excluded.
* Subjects deemed by the Investigator to have any condition compromising safety, data integrity, or study compliance will be excluded.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No